The synthesis, cell origin, and physiologic role of eicosanoids were investigated in a model of mesangial cell immune injury induced by a monoclonal antibody against the rat thymocyte antigen Thy 1.1 also expressed in rat mesanial cells. A single intravenous injection of the antibody resulted in enhanced glomerular synthesis ofthromboxane (Tx)B2, leukotriene (LT)B4, and 12-hydroxyeicosatetraenoic acid (HETE), whereas that of PGE2 and PGF2a was either unaltered or impaired. The enhanced eicosanoid synthesis was associated with decrements in glomerular filtration rate (GFR) and renal blood flow (RBF). Complement activation mediated both the increments in TxB2, LTB4, and 12-HETE and the decrements in GFR and RBF. The decrements in GFR were abolished by the TxA2 receptor antagonist SQ-29,548. Although both neutrophiles and Ia (+) leukocytes infiltrated glomeruli, glomerular LTB4 originated mainly from the latter. Platelets entirely accounted for the enhanced 12-HETE synthesis in isolated glomeruli and to a lesser extent for that of LTB4 and TxB2. Glomerular PGE2 and PGF2a originated from mesangial cells as their impaired synthesis coincided with extensive mesangial cell lysis. The observations indicate that in mesangial cell immune injury vasoactive and proinflammatory eicosanoids originate from recruited or activated Ia (+) leukocytes and platelets and may exert paracrine effects on mesangial cells. (J. Clin. Invest. 1991. 88:623-631.)
Introduction
The Thy-1 gene is a member of the immunoglobulin "super family" of genes and is expressed in a number of different cell types (1) . The expression product is a 17-kD cell surface antigenic glycoprotein (the Thy-l antigen) that is expressed in thymocytes, young lymphocytes, and their precursor hematopoietic stem cells, in fibroblasts and in neurons ofthe central nervous system (1) . Rat glomerular mesangial cells have also been shown to express the Thy-1.l antigen (2) . In Thy-1-bearing cells this antigen is anchored to the acyl chains of membrane phosphatidylinositol and can be cleaved by a phosphatidylino-sitol-specific phospholipase C (3) . A monoclonal antibody (ER4, IgG2A), raised against the rat thymocyte antigenic determinant Thy 1.1, binds to rat glomerular mesangial cells and induces a complement-dependent injury resulting in mesangial cell lysis, followed by a mesangioproliferative phase (4) . This model of glomerular immune injury can, therefore, be regarded as the experimental equivalent ofnephropathies involving primarily the glomerular mesangium, and provides the opportunity to investigate the biology ofmesangial cell injury as it relates to synthesis of proinflammatory mediators and renal hemodynamic perturbations. We, therefore, investigated the biosynthesis, cell origin, and role of vasoactive and proinflammatory arachidonate cyclooxygenation and lipoxygenation products.
Methods
Induction ofmesangial cell immune injury. Mesangial cell injury was induced by a single intravenous administration ofthe mouse monoclonal antibody (ER&) raised against the rat thymocyte antigenic determinant Thy 1.1 and generously provided by Dr. W. Bagchus, Department of Pathology, University of Groningen, The Netherlands. This antibody (molecular weight 25 kD) binds to thymocytes, bone marrow cells, peripheral blood lymphocytes, and to mesangial cells, and also demonstrates complement binding capacity (4) . Male Munich-Wistar rats (165-290 g body wt) were employed and, in most experiments, two antibody doses were employed: a 2.5 and a 6 mg/kg body wt. Both doses induced proteinuria (urine protein excretion: 207±9 mg/24 h) and glomerulonephritis. The 6-mg/kg dose also induced decrements in glomerular filtration rate and renal blood flow (see below). Glomerular and mesangial cell lesions were assessed in cortical sections by routine methods of light and immunofluorescence microscopy. Light microscopy assessed changes in glomerular and mesangial cell morphology in 4-5-M cortical sections stained with the Hematoxylin-Eosin and Periodic acid Schiffstains as well as the presence ofblood-borne leukocytes in sections stained with the Giemsa stain. Immunofluorescence microscopy (direct) was performed in 7-8-A cortical sections and assessed deposition and distribution of the ER4 antibody using FITC-labeled goat anti-mouse IgG and of rat complement component C3 using FITC-labeled goat anti-rat C3. The presence of Ia (+) cells was also assessed by direct immunofluorescence using an FITC-labeled mouse monoclonal antibody against the rat monocyte/macrophagela determinant (Sera-Lab, Sussex, England). The presence of Ia (+) and bloodborne leukocytes (neutrophils) was expressed as number of cells per glomerulus (mean±SEM, n = 20 glomeruli).
Biochemistry studies. These studies were performed at two early points (1 and 2 h) and at two late points (day 4 and day 14) after ER4 antibody administration. At these time points, animals were nephrectomized and the kidneys were placed in RPMI-1640 at 4°C. Glomeruli were isolated by differential sieving, suspended in 2 ml ofRPMI-1640, and incubated under constant stirring at 37°C for 30 min. At the end of this incubation period, an aliquot of the medium (100-200 ul) was sampled and assayed directly for PGE2, PGF2a, and TxB2 using specific RIA for these eicosanoids as previously described (5) . In the remaining glomerular suspension, the phospholipase A2 activator A23187 arachidonate lipoxygenation products 12-hydroxyeicosatetraenoic acid (HETE)' and leukotriene (LT)B4. A second incubation in the presence ofA23187 was performed at 370C for 45 min and was terminated by the addition of 2 vol of acidified absolute ethanol. After prolonged agitation at 40C, the ethanolic mixture of the glomerular suspensions was centrifuged in order to separate glomeruli and precipitated proteins. The supernatant was dried under vacuum, suspended in 1 ml of methanol:water:acetic acid (64:34:2 vol/vol/vol), and injected in a gradient HPLC system in order to separate and isolate HETE and leukotrienes, as previously described (6) . HPLC-isolated 12-HETE and LTB4 were subsequently measured using specific RIAs as previously described (6) . The glomerular pellet was solubilized in 0.1 N sodium hydroxide and used for protein determination by a colorimetric method. Results were expressed in nanograms of eicosanoid/mg glomerular protein. Sensitivities and cross-reactivities of the RIAs employed for the above eicosanoids were previously assessed and reported (6 Physiology studies. These studies assessed the effect of intravenous ER4 antibody administration on changes in glomerular filtration rate (GFR) and renal blood flow (RBF) . Animals were anesthetized with intraperitoneal thiobutabarbitol (Inactin; Byk, Gulden Konstanz, FRG), 12-15 mg/100 g body wt, and maintained at 37°C by warming on a constant temperature table. After tracheostomy, a catheter was placed in the right jugular vein for infusion of 2% albumin in 0.9% sodium chloride at a rate of20 ml/kg per h throughout the experiment. Tritiated inulin, 0.5 ,Ci/ml, was added to the infusion solution for measurement of GFR. The right femoral artery was cannulated for measurement of systemic blood pressure via a transducer connected to a digital pressure monitor and for collection of blood samples. Catheters were inserted into the right and left ureters for urine collection. A flow probe (1.5-2.0 mm) was placed around the left renal artery and RBF was measured using an electromagnetic flow meter (model 501; Carolina Instruments, King, NC). After completion of surgery and a 60-min stabilization period, two baseline clearance periods (15 min each) were obtained. Animals subsequently received a single intravenous injection of ER4 antibody (6 mg/kg) or mouse IgG (controls, 6 mg/kg) and urine and plasma samples were collected for determination of GFR at 1 h after administration of ER4.
In a second group of animals, GFR and RBF were assessed after decomplementation in order to determine the role of complement in mediating the ER4 antibody-induced changes in these parameters. Decomplementation was achieved by the intraperitoneal injection of cobra venom factor (CVF; Cordis, Miami, FL) purified by ion exchange and gel filtration chromatography (7) . 100 U per 100 g body wt was administered in four divided doses over the 24-h period preceeding measurements of GFR and RBF. Animals were subsequently instrumented and GFR and RBF were measured as described above. Upon completion of these measurements rats were nephrectomized and glomeruli were isolated for assessment ofeicosanoid synthesis as described above. Systemic decomplementation was assessed by a modified hemolytic assay, performed in serum samples obtained from the tail vein at baseline and before initiation ofthe physiologic studies. To perform the assay, sensitized sheep red blood cells, 1 X I09 cells/ml, were incubated with varying dilutions of serum samples at 37°C for 1 h and subse- Leukocyte andplatelet depletion studies. Glomerular Ia (+) leukocytes were depleted by the use ofa whole animal x irradiation protocol as previously described (8) . Specifically, animals were subjected to 250
KVp orthovoltage x rays with a half value of 1 mm Cu at a dose rate of 133 rad/min for a total dose of 900-1,100 rad, using parallel opposed fields. Kidneys were shielded with 6-mm thick lead blocks that covered the kidneys within 5 mm margins. Positioning of the blocks was verified with diagnostic x rays done simultaneously with treatment (port fields). Dosimetry was done in a plexiglass phantom using a Farmertype ionization chamber. The effect of x irradiation was assessed on peripheral leukocyte counts determined by an automated hematology analyzer (Coulter Electronics, Hialeah, FL) before administration of ER4 and on glomerular Ia (+) cells, neutrophil counts, and LTB4 synthesis at 2 h after ER4. These studies employed three groups ofrats that were studied at 24, 72, and 96 h after the x irradiation dose.
To deplete animals of circulating platelets, a rabbit anti-rat thrombocyte immune serum was employed (Accurate Co., Westbury, NY). A single intraperitoneal injection of 1.5 ml of this serum resulted in marked and selective systemic platelet depletion within 18-24 h and was associated with prolongation in the bleeding time. After platelet depletion was confirmed in each animal by an automated hematology analyzer (Coulter Electronics), ER4 antibody (2.5 mg/kg) was injected and glomeruli were isolated 2 h later for determination of eicosanoid synthesis as described above.
In vitro eicosanoid synthesis. To assess whether binding ofanti-Thy 1 antibody in the glomerular mesangium in vitro induces eicosanoid synthesis, glomeruli isolated from normal animals were subjected to mild enzymatic permeabilization in Hank's balanced salt solution containing 1% Hepes, collagenase Type 11, 50 U/ml (Sigma Chemical Co., St. Louis, MO), and DNAse 0.01% (Sigma Chemical Co.). After washing off the permeabilization solution, glomeruli were incubated with ER4 antibody (2 mg/ml; n = 4) or mouse IgG (2 mg/ml; n = 4) in the presence of 10% rat serum or plasma as a source ofcomplement. Incubations were performed at 37°C for 45 min in a manner similar to that employed in glomeruli isolated from animals that had received ER4 injections. Binding of ER4 antibody and of rat complement C3 to the glomerular mesangium was documented by immunofluorescence microscopy in an aliquot ofglomeruli at the end ofthe incubations. Glomerular incubations were terminated by the addition of 2 vol of absolute ethanol, and extracts were processed for isolation and quantification of LTB4 and 12-HETE using HPLC and RIA as described above. 3. Studies in x irradiated animals. These were performed at 24 h (n = 6), at 72 h (n = 6), or at 96 h (n = 6) after x irradiation. At these time points animals received ER4 antibody (2.5 mg/kg) and glomerular eicosanoid synthesis was assessed 2 h later.
4. Platelet depletion studies. Animals received a single injection of anti-thrombocyte serum 18-24 h before ER4 antibody (2.5 mg/kg; n = 6). Glomerular eicosanoid synthesis was assessed at 2 h after injection of ER4.
Statistical analyses employed the two-way analysis of variance for repeated measurements followed by a Duncan multiple range test and the Student's t test for unpaired observations, as dictated by the experimental designs. Results were expressed as mean±SEM.
Results
Effects of ER4 on glomerular histopathology. Fig. 1 demonstrates glomerular deposition of the monoclonal antibody ER4 at 1 h (Fig. 1 A) and 14 d (Fig. 1 B) after a single intravenous injection. The antibody initially localized in the glomerular mesangium ( Fig. 1 A) . It subsequently redistributed towards peripheral glomerular capillary loops (Fig. 1 B) . Fig. 2 demonstrates the presence of glomerular Ta (+) cells in a control glomerulus ( Fig. 1 A) , at 2 h (Fig. 2 B) , and on day 14 ( Fig. 2 C) after a single intravenous injection of the ER4 antibody. There was an increase in Ta (+) cells throughout the glomerulus at 2 h and a sustained increment in these cells on day 14, at which point their location was peripheral. Fig. 3 demonstrates the changes in glomerular cellularity at various time points after ER4 antibody administration. Increased cellularity was noted at 1 to 2 h (Fig. 3 B) compared with control ( Fig. 3 A) . On day 4 ( Fig. 3 C) , glomerular hypocellularity with marked absence of mesangial cells was apparent. On day 14 (Fig. 3 D) , glomerular cellularity recovered and there was also an increase in mesangial matrix.
Effects ofER4 on glomerular eicosanoid synthesis: correlation with leukocyte infiltration. In Fig. 4 the changes in glomerular synthesis of TxB2, PGE2, and PGF2a compared with pooled synchronous controls are shown at the various time points after a single intravenous administration of ER4 antibody (2.5 mg/kg). There was a progressive and sustained increment in TxB2 that spanned all time points ofstudy. In contrast, the synthesis of PGE2 and PGF2a progressively declined and reached a nadir on day 4. The synthesis of these two eicosanoids subsequently recovered (day 14) to control levels.
In Fig. 5 the glomerular synthetic profiles of LTB4 and 12-HETE, at the various time points after a single intravenous injection of ER4 (2.5 mg/kg), are shown in parallel with LTB4 and 12-HETE values obtained in synchronous controls. The synthesis of 12-HETE in animals receiving ER4 was significantly enhanced at 2 h after antibody administration and remained increased at statistically significant levels at all subsequent time points compared with synchronous controls. In contrast to 12-HETE, significant increments in glomerular LTB4 synthesis occurred earlier (1 h) but spanned a shorter period of time and returned toward control levels on day 4. LTB4 synthesis remained significantly higher than synchronous controls on day 4 (0.51+0.10 vs. 0.24±0.04; P < 0.05) and was no different than controls on day 14. Counts of both cell types were significantly higher at all time points compared with synchronous controls. Whereas the increments in glomerular 12-HETE and LTB4 were temporarily associated with the increments in glomerular Ta (+) and neutrophil cell counts at 1 and 2 h after administration ofER4 (Figs. 5 and 6) , at later time points (days 4 and 14) , LTB4 values returned toward control levels (Fig. 5) despite a sustained increase in glomerular Ta (+) cell and neutrophil counts (Fig. 6 ).
12-HETE synthesis remained significantly increased at all time points.
Eicosanoids and Mesangial Nephritis 625 Effects ofx irradiation and ofplatelet depletion on glomerular eicosanoid synthesis. Table I demonstrates the correlation between glomerular LTB4 synthesis and glomerular neutrophil and Ia (+) cell counts determined 2 h post-ER4 and peripheral leukocyte counts assessed before ER4 administration in the three groups of animals studied at 24, 72, and 96 h after x irradiation dose. Peripheral leukopenia and a relative reduction in glomerular neutrophils after x irradiation were present in all groups. Post-ER4 glomerular LTB4 synthesis was significantly reduced only in glomerular preparations isolated from animals studied 96 h after x irradiation. In this group glomerular Ia (+) cell counts were also abolished. In the groups studied 24 and 72 h post-x irradiation, although marked peripheral leukopenia and glomerular reduction ofneutrophils were present, glomerular LTB4 synthesis measured 2 h post-ER4 was not different compared with levels obtained in glomeruli isolated from nonirradiated rats studied 2 h after ER4 antibody administration (Table I) There isadichotomy in synthetic profiles of these three eicosanoids most notable on day 4. *P < 0.05, TxB2 compared with pooled controls. tP < 0.05, PGE2 and PGFu compared with pooled controls.
The effect of platelet depletion and of x irradiation on glomerular TxB2, 12-HETE, and LTB4 synthesis assessed at 2 h after administration ofER4 (2.5 mg/kg) is shown in Fig. 7 . The ER4-induced increments in glomerular 12-HETE synthesis were abolished in the platelet-depleted group compared with the group that received ER4 antibody alone (Fig. 7) . In this group, glomerular TxB2 and LTB4 synthesis were also significantly reduced; however, they remained significantly higher compared with control values. In the x irradiated group (96 h postirradiation), glomerular TxB2 and 12-HETE synthesis were not significantly different compared with the group that received ER4 antibody alone. In contrast, LTB4 synthesis was significantly reduced.
The antiplatelet antibody employed markedly reduced cir- In vitro effect of ER4 antibody on glomerular eicosanoid synthesis. Fig. 8 demonstrates binding of ER4 antibody (Fig. 8  A) and of rat C3 (Fig. 8 B) in isolated enzymatically permeabilized glomeruli incubated with the monoclonal antibody ER4 (2 mg/ml) in the presence of 10% rat serum (source ofcomplement). IgG and stained for rat C3. There was no change in glomerular LTB4 synthesis in permeabilized glomeruli incubated with ER4 antibody compared with control glomeruli incubated with mouse IgG (LTB4: 0.9±0.2 ng/mg glomerular protein in glomeruli incubated with ER4 and 1.7±0.2 ng/mg glomerular protein in glomeruli incubated with mouse IgG). Because the rat serum used as a source of complement was found to contain high levels of 12-HETE (866 ng/ml of serum containing medium), two additional experiments using rat plasma as a complement source were performed in order to assess changes in glomerular 12-HETE synthesis in response to ER4 binding. The levels of 12-HETE in rat plasma containing media were 47 ng/ml. In permeabilized glomeruli incubated with ER4 (2 ng/ ml) in the presence of 10% rat plasma 12-HETE synthesis was 206 ng/mg glomerular protein. In control glomeruli incubated with mouse IgG 12-HETE synthesis was 260 ng/mg protein.
Effects ofER4 on GFR and RBF: role ofcomplement and of Tx receptor antagonism. Fig. 9 demonstrates the effect ofcomplement depletion and of thromboxane receptor antagonism with SQ-29,548 on ER4 antibody-induced decrements in GFR and RBF. The glomerular eicosanoid synthetic profiles corresponding to the four groups ofanimals studied and determined upon completion of the GFR and RBF measurements are shown in Table II . In both the complement-depleted group and the SQ-29,548-treated group the decrements in GFR and RBF were ameliorated to levels not different from each other and significantly higher than the group receiving ER4 alone. In the SQ-29,548-pretreated rats, GFR and RBF values were no different compared with the decomplemented group of rats receiving mouse IgG (controls). In the decomplemented group receiving ER4, the glomerular synthesis of TxB2, LTB4, and 12-HETE were significantly lower compared with the complement replete group receiving ER4 (Table II) . In the SQ-29,548-pretreated group the synthesis of these eicosanoids was no different than the group receiving ER4 alone.
Discussion
Enhanced eicosanoid synthesis in isolated glomeruli has been demonstrated in various forms of experimental and clinical glomerulopathies. Studies have focused on identifying the type of eicosanoid(s) synthesized after initiation of immune injury and their role in mediating vasoactive and proinflammatory events occurring in the progression ofinjury. Increased synthesis of both arachidonate cyclooxygenation and lipoxygenation metabolites has been demonstrated (9) . Of the former, increased glomerular synthesis of thromboxane has been consistently shown in most forms of antibody-mediated renal injury and has been implicated in effecting adverse hemodynamic effects such as decrements in GFR and RBF (9) . Ofthe (11), and essential fatty acid-deficient diets inhibit glomerular LTB4 synthesis and ameliorate the hemodynamic and histopathological severity of anti-GBM glomerular injury (12) . The cell of origin of "glomerular" eicosanoids has been an issue of debate. In antibody-mediated models of glomerular immune injury, it seemed reasonable to assume that the injured glomerular cell was a likely source of eicosanoids. This was a particularly reasonable assumption in models employing antibodies directed against antigens of specific glomerular cells (i.e., antibodies against the FxlA antigen ofglomerular epithelial cells) that, when cultured, were capable of eicosanoid synthesis. This assumption was strengthened further when the role of hematogenous cells capable of eicosanoid synthesis was assessed in infiltrative models of glomerular immune injury. Thus, in anti-GBM disease, an infiltrative form of experimental glomerulonephritis, it was demonstrated that platelets did not contribute to the enhanced glomerular 12-HETE synthesis (13) and, in the same disease model, neutrophil depletion only partially contributed to the enhanced glomerular LTB4 synthesis (6). Likewise, in a different model of infiltrative glomerulonephritis, induced by administration ofcationized gamma globulin, enhanced glomerular LTB4 synthesis persisted in neutropenic rats (10) . Several lines ofevidence, however, indicate that cells other than those on which immunologic reactants (i.e., antibody and complement components) bind may account for the enhanced eicosanoid synthesis observed in glomeruli isolated after initiation of injury. synthesize measurable amounts of LTB4 and 12-HETE when incubated with the phospholipase A2 activator, A23187 (6) , yet, none of the glomerular cell populations in culture (epithelial, mesangial, endothelial) express the arachidonate 5-lipoxygenase gene (14, 15) . (b) In glomerular epithelial cell injury mediated by anti-FxlA antibody, there is enhanced glomerular LTB4 synthesis despite the fact that glomerular epithelial cells in culture do not synthesize LTB4 and glomeruli do not show infiltration by leukotriene-producing cells (i.e., leukocytes) after anti-FxlA administration (16) . (c) Diets deficient in essential fatty acids, or bone marrow depletion using whole animal x irradiation, abolish glomerular LTB4 synthesis, and this event was convincingly correlated with depletion ofglomerular Ia-bearing monocytes (17) , an observation that points to this cell type as a likely source ofarachidonate lipoxygenation products in glomeruli.
On the basis of these controversial observations, we reasoned that because the eicosanoid synthetic profile of mesangial cells is well characterized (18) and the role of mesangial cells in regulating glomerular filtration emphasized (19) , the model of anti-Thy 1 antibody-induced mesangial cell injury is most suitable to study origin and physiologic role of eicosanoids. The demonstration that the Thy-I antigen is specifically linked to membrane phosphatidylinositol in Thy-l-bearing cells (3), lends further suitability to this model of immune injury for study of the origin and role of eicosanoids.
Our observations indicate that in mesangial cell immune injury induced by the monoclonal anti-Thy 1 antibody ER4, cells other than the injured mesangial account for the enhanced glomerular eicosanoid synthesis. Moreover, different cells account for the synthesis of different eicosanoids. This is best illustrated in Fig. 4 , where the dichotomy in the synthesis ofthe three arachidonate cyclooxygenation products, PGE2, PGF2a, and TxB2 is shown. This dichotomy is most apparent on day 4, when TxB2 synthesis was at a maximum, while that of PGE2 and PGF2a was at a minimum and at levels lower than controls. As the nadir in PGE2 and PGE2a synthesis (Fig. 4) correlated with glomerular hypocellularity and mesangial cell depletion (Fig. 3 C) , we propose that the origin ofthese two eicosanoids is the mesangial cell. This contention is supported by the well established profile of eicosanoids in cultured mesangial cells that includes primarily PGE2 and PGF2a (18) . The recovery in PGE2 and PGF2a synthesis on day 14 after administration of ER4 (Fig. 4) could be due to a mesangioproliferative phase (Fig. 3 D) , which follows the mesangiolytic phase as previously described in this model (4, 20) .
That the Ia (+) leukocyte is a likely source of glomerular LTB4 is supported by the following two observations: (a) In x Figure 8 . Binding of the ER4 antibody (A) and rat C3 (B) in isolated enzymatically permeabilized normal glomeruli. C is a control glomerulus stained for C3. irradiated animals, enhanced glomerular LTB4 synthesis determined 2 h post-ER4 continued in a manner independent of peripheral leukocyte counts and of glomerular neutrophil counts (Table I) . It was abolished only in animals studied 96 h after x irradiation, when glomerular Ia (+) cell counts were also abolished (Table I) ; (b) binding of ER4 in permeabilized glomeruli ( Fig. 8) originating from normal animals and in the presence of rat serum did not result in enhanced LTB4 or 12-HETE synthesis. Cell types possessing the Ia antigen that could account for the enhanced glomerular LTB4 synthesis include: elicited monocyte-macrophages, activated lymphocytes, activated glomerular endothelial cells, and the mesangial cell itself (21) . As there is no evidence that lymphocytes synthesize 5-HETE or LTB4 (22) , or that glomerular epithelial, endothelial, or mesangial cells express the 5-lipoxygenase gene ( 14) , we propose that the Ia (+) monocyte-macrophage is the likely source of LTB4. Our observations do not entirely rule out the neutrophil as a potential source of LTB4. As shown in Figs. 5 and 6, the increments in glomerular LTB4 at 1 and 2 h coincided with increments in both glomerular la (+) and neutrophil counts. However, on days 4 and 14 after ER4, LTB4 synthesis returned toward control levels despite significant glomerular infiltration by neutrophils (Fig. 6 ). Moreover, in x irradiated leukopenic animals, glomerular depletion of neutrophils did not result in decreased glomerular LTB4 synthesis after ER4 ( (Table II) and this might be accounted for by the effect of complement activation and anaphylatoxin release on glomerular leukocyte infiltration. In addition, it is possible that binding of anaphylatoxin (CSa), generated after intraglomerular complement activation, on Ia-bearing macrophages results in enhanced LTB4 synthesis either directly or via a mechanism involving IL-1. Specific receptors for C5a have been demonstrated on murine Ia-bearing macrophages and binding ofC5a on these receptors induces IL-I secretion (23) . IL-1, in turn, is a known eicosanoid synthesis agonist. The dependence of glomerular LTB4 synthesis on platelets is intriguing (Fig. 7) , mainly because platelets do not synthesize LTB4. Thus, this observation raises the possibility for a platelet/leukocyte interaction resulting in LTB4 synthesis. The platelet could generate an eicosanoid synthesis agonist (i.e., PDGF or TGF-fl). It may provide arachidonate, which can subsequently undergo 5-lipoxygenation to LTB4 by 5-lipoxygenasecontaining leukocytes (24) , or it may augment LTB4 production by leukocytes through a mechanism involving generation of (25) . In the latter case, however, one would expect the enhanced glomerular 12-HETE synthesis to preceed that of LTB4, an event that was not noted in our time course studies (Fig. 5) , which demonstrate that the enhanced LTB4 synthesis preceeded that of 12-HETE. The complement system may also play a role in mediating platelet recruitment and/or activation, thereby promoting platelet-leukocyte interactions. In mesangial cell injury induced by a polyclonal rabbit anti-rat thymocyte antibody, it was demonstrated that complement depletion using CVF reduced glomerular platelet infiltration (26) . As can be concluded from Fig. 7 , platelets accounted for the glomerular 12-HETE and TxB2 synthesis. Of these two eicosanoids, the effect on 12-HETE was the most striking. In contrast, TxB2 levels remained elevated compared with controls. In contrast to platelet depletion, x irradiation, followed by a 96-h waiting period, had no effect on glomerular TxB2 or 12-HETE synthesis (Fig. 7) . As this x irradiation protocol depletes glomeruli of Ia-bearing monocytes (reference 8 and Table I ), our observations indicate that this cell population does not entirely account for the sustained increments in glomerular TxB2 or 12-HETE synthesis after administration of ER4. This contrasts with the observations of Stahl and co-workers, who reported a monocyte dependence of glomerular TxB2 synthesis in a model of mesangial cell injury using rabbit polyclonal antibody against the rat thymocyte (27). This discrepancy could be due to the different experimental approaches employed in order to deplete monocytes, namely, immune monocytopenia (27) versus x irradiation, which causes bone marrow depletion and progressive glomerular Ia (+) cell depletion.
Our data indicate that the protective effect of complement depletion on GFR and RBF was associated with decreased glomerular synthesis of TxB2, LTB4, and 12-HETE (Table II) . The protective effect of decomplementation can be accounted for by the decrements in thromboxane synthesis, as pretreatment with the TxA2 receptor antagonist SQ-29,548 ameliorated the ER4-induced decrements in GFR to an extent similar to that noted in decomplemented animals ( Fig. 9 ) and had no effect on TxB2, LTB4, or 12-HETE synthesis (Table II) . That thromboxane mediates the acute decrements in GFR is also supported by the recent observations of Stahl and co-workers, who demonstrated that thromboxane synthase inhibition ameliorated the anti-thymocyte antibody-induced decrements in GFR (27) . Whether the enhanced synthesis of LTB4 or 12-HETE have a vasoactive effect and contribute to the decrements in GFR is speculative. A synergistic effect to thromboxane is likely because 12-HETE has recently been shown to vasoconstrict the rat vasculature (28) and essential fatty acid-deficient diets inhibit glomerular LTB4 and ameliorate decrements in GFR and RBF in glomerular immune injury induced by anti-GBM antibody (12) . The availability of specific 12-lipoxygenase or 5-lipoxygenase inhibitors should allow definitive conclusions to be made on the role of 12-HETE and LTB4 in mediating the decrements in GFR and RBF. Moreover, study of the effect of platelet depletion on renal hemodynamic perturbations occurring in mesangial cell immune injury would allow unravelling of the role of platelet-derived vasoactive eicosanoids, such as Tx and 12-HETE.
In summary, we have demonstrated that the enhanced synthesis ofeicosanoids in glomeruli isolated from rats with mesangial cell immune injury originates from cells other than the mesangial cell. The la (+) leukocyte is a likely source of LTB4 by a mechanism involving interactions with the complement system and the platelet. The stimulus for LTB4 synthesis, however, is short lived and the participation of the neutrophil cannot be entirely ruled out. The platelet entirely accounts for the enhanced 12-HETE and partially accounts for the enhanced thromboxane synthesis. Complement activation mediates the acute decrements in GFR and RBF after mesangial cell injury via a mechanism involving enhanced eicosanoid synthesis and specifically thromboxane.
Our observations are of significance in that they implicate the platelet and the leukocyte as sources of proinflammatory and vasoactive eicosanoids in mesangial cell immune injury. Both cell types are capable ofsynthesizing and releasing potent noneicosanoid proinflammatory factors that can mediate proliferation (i.e., PDGF), matrix synthesis (i.e., TGF-#l), cytotoxicity (i.e., TNF), and immunoregulation (interleukins). The timed or sustained synthesis of specific eicosanoids by these cells may, therefore, play an important role in regulating the synthesis or release of these proinflammatory factors in an autocrine or paracrine manner.
